Re Directorate-Replacemnt

Phytopharm PLC
22 September 2000

The issuer has made the following amendment to the 'Re Directorate'
announcement released at 12:32 under RNS No 3859R.

The following sentence was omitted from the announcement 'In addition, the
Company advises that there are no matters under paragraph 6F2 (b) to (g) of the
Listing Rules to be disclosed in relation to Dr Rees.'

The full corrected version is shown below.
-------------------------------------------------------------------

22 September 2000

                                Phytopharm plc
                               Board Appointment


Phytopharm  plc  (PYM:  London Stock Exchange) ('Phytopharm')  is  pleased  to
announce  that  Dr  Daryl  Rees  has been appointed  to  the  Board  as  Chief
Scientific  Officer.  In  this  role  he  will  have  responsibility  for  the
scientific strategy of Phytopharm's research and development programmes.

Dr Rees joined Phytopharm in June 1999 from University College London where he
was a Senior Lecturer in Clinical Pharmacology.  Prior to this, Dr Rees gained
10 years' experience in the discovery and clinical development of medicines as
a  Senior  Scientist  at  Wellcome and was part of a  multi-disciplinary  team
involved  in  the discovery of the L-arginine-NO pathway.  He is  an  Honorary
Senior Lecturer in the Department of Medicine at University College London,  a
former  Editor of the British Journal of Pharmacology, a member of the British
Pharmacological Society, the British Hypertension Society, the European  Shock
Society  and  is  Chairman  designate  of  Huntingdon  Local  Research  Ethics
Committee.

Commenting  on his appointment, Richard Dixey, Chief Executive of  Phytopharm,
said:
'Daryl  has  a  wealth of experience in the development of  novel  therapeutic
agents and has played a key role in the successful progression of Phytopharm's
lead  clinical  candidates for Alzheimer's disease (P58),  Inflammatory  Bowel
Disease  (P54),  Eczema (P55) and Obesity (P57), as well as encouraging  rapid
development of the Company's preclinical portfolio. We are very pleased to see
someone with Daryl's experience being appointed to Phytopharm's Board.'

In addition, the Company advises that there are no matters under paragraph 6F2
(b) to (g) of the Listing Rules to be disclosed in relation to Dr Rees.


Enquiries:

Phytopharm plc                                   Tel:  [phone]
Richard Dixey, Chief Executive

Financial Dynamics                               Tel:  [phone]
David Yates / Sophie Pender-Cudlip



NOTES TO EDITORS
Phytopharm plc
Phytopharm's business is to take both simple and complex mixtures derived from
plant  sources  into full pharmaceutical development.  The US  Food  and  Drug
Administration call such medicinal products 'Botanicals'.  Botanical  products
are  whole  or  partially purified extracts of medicinal plants in  which  the
chemical composition is not fully characterised. Apart from being a new sector
in the pharmaceutical market, Botanicals also act as an enabling technology to
discover single chemical entities of clinical importance from plant sources.
Phytopharm   is   the  leading  company  in  the  development   of   botanical
pharmaceuticals.  It has developed a portfolio of 11 such  products,  nine  of
which are in the clinical evaluation phase.  These products have been targeted
in   the   five   therapeutic  categories  of  anti-inflammatory   treatments,
neurological disorders, dermatology, cancer and metabolic diseases.  In  1997,
Phytopharm was granted an Investigational New Drug (IND) approval in  the  US.
The  guidelines for the registration of botanical products have recently  been
published by the FDA.
More  information concerning Phytopharm's activities can be found on  its  Web
site at http://www.phytopharm.co.uk.